Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Castrate Resistant Prostate Cancer (CRPC) 1

Interventions

Doxorubicin 80Ifosfamide 54Radiotherapy 43Filgrastim 41Gemcitabine 38Cyclophosphamide 34Etoposide 26Vincristine 24Cisplatin 24Docetaxel 23pazopanib 21Trabectedin 19Carboplatin 17pembrolizumab 15Peripheral Blood Stem Cell Transplantation 14eribulin 12Mesna 12Melphalan 12Sorafenib 11Sirolimus 11Irinotecan 11Granulocyte Colony-Stimulating Factor 11Bevacizumab 11Topotecan 10Paclitaxel 10Imatinib Mesylate 10Chemotherapy, Adjuvant 10pegfilgrastim 9Temozolomide 9Surgical Procedures, Operative 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma × AP 1903 reagent × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡